Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial

A. West, N. Chaudhuri, A. Barczyk, ML. Wilsher, P. Hopkins, I. Glaspole, TJ. Corte, M. Šterclová, A. Veale, E. Jassem, MS. Wijsenbeek, C. Grainge, W. Piotrowski, G. Raghu, ML. Shaffer, D. Nair, L. Freeman, K. Otto, AB. Montgomery

. 2023 ; 78 (9) : 882-889. [pub] 20230322

Language English Country England, Great Britain

Document type Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23016455
E-resources Online Full text

NLK ProQuest Central from 1946-03-01 to 6 months ago
Open Access Digital Library from 1946-03-01
Health & Medicine (ProQuest) from 1946-03-01 to 6 months ago

Links

PubMed 36948586
DOI 10.1136/thorax-2022-219391
Knihovny.cz E-resources

INTRODUCTION: Oral pirfenidone reduces lung function decline and mortality in patients with idiopathic pulmonary fibrosis (IPF). Systemic exposure can have significant side effects, including nausea, rash, photosensitivity, weight loss and fatigue. Reduced doses may be suboptimal in slowing disease progression. METHODS: This phase 1b, randomised, open-label, dose-response trial at 25 sites in six countries (Australian New Zealand Clinical Trials Registry (ANZCTR) registration number ACTRN12618001838202) assessed safety, tolerability and efficacy of inhaled pirfenidone (AP01) in IPF. Patients diagnosed within 5 years, with forced vital capacity (FVC) 40%-90% predicted, and intolerant, unwilling or ineligible for oral pirfenidone or nintedanib were randomly assigned 1:1 to nebulised AP01 50 mg once per day or 100 mg two times per day for up to 72 weeks. RESULTS: We present results for week 24, the primary endpoint and week 48 for comparability with published trials of antifibrotics. Week 72 data will be reported as a separate analysis pooled with the ongoing open-label extension study. Ninety-one patients (50 mg once per day: n=46, 100 mg two times per day: n=45) were enrolled from May 2019 to April 2020. The most common treatment-related adverse events (frequency, % of patients) were all mild or moderate and included cough (14, 15.4%), rash (11, 12.1%), nausea (8, 8.8%), throat irritation (5, 5.5%), fatigue (4, 4.4%) and taste disorder, dizziness and dyspnoea (three each, 3.3%). Changes in FVC % predicted over 24 and 48 weeks, respectively, were -2.5 (95% CI -5.3 to 0.4, -88 mL) and -4.9 (-7.5 to -2.3,-188 mL) in the 50 mg once per day and 0.6 (-2.2 to 3.4, 10 mL) and -0.4 (-3.2 to 2.3, -34 mL) in the 100 mg two times per day group. DISCUSSION: Side effects commonly associated with oral pirfenidone in other clinical trials were less frequent with AP01. Mean FVC % predicted remained stable in the 100 mg two times per day group. Further study of AP01 is warranted. TRIAL REGISTRATION NUMBER: ACTRN12618001838202 Australian New Zealand Clinical Trials Registry.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016455
003      
CZ-PrNML
005      
20231026105809.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/thorax-2022-219391 $2 doi
035    __
$a (PubMed)36948586
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a West, Alex $u Guy's and St Thomas' Hospital, London, UK
245    10
$a Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial / $c A. West, N. Chaudhuri, A. Barczyk, ML. Wilsher, P. Hopkins, I. Glaspole, TJ. Corte, M. Šterclová, A. Veale, E. Jassem, MS. Wijsenbeek, C. Grainge, W. Piotrowski, G. Raghu, ML. Shaffer, D. Nair, L. Freeman, K. Otto, AB. Montgomery
520    9_
$a INTRODUCTION: Oral pirfenidone reduces lung function decline and mortality in patients with idiopathic pulmonary fibrosis (IPF). Systemic exposure can have significant side effects, including nausea, rash, photosensitivity, weight loss and fatigue. Reduced doses may be suboptimal in slowing disease progression. METHODS: This phase 1b, randomised, open-label, dose-response trial at 25 sites in six countries (Australian New Zealand Clinical Trials Registry (ANZCTR) registration number ACTRN12618001838202) assessed safety, tolerability and efficacy of inhaled pirfenidone (AP01) in IPF. Patients diagnosed within 5 years, with forced vital capacity (FVC) 40%-90% predicted, and intolerant, unwilling or ineligible for oral pirfenidone or nintedanib were randomly assigned 1:1 to nebulised AP01 50 mg once per day or 100 mg two times per day for up to 72 weeks. RESULTS: We present results for week 24, the primary endpoint and week 48 for comparability with published trials of antifibrotics. Week 72 data will be reported as a separate analysis pooled with the ongoing open-label extension study. Ninety-one patients (50 mg once per day: n=46, 100 mg two times per day: n=45) were enrolled from May 2019 to April 2020. The most common treatment-related adverse events (frequency, % of patients) were all mild or moderate and included cough (14, 15.4%), rash (11, 12.1%), nausea (8, 8.8%), throat irritation (5, 5.5%), fatigue (4, 4.4%) and taste disorder, dizziness and dyspnoea (three each, 3.3%). Changes in FVC % predicted over 24 and 48 weeks, respectively, were -2.5 (95% CI -5.3 to 0.4, -88 mL) and -4.9 (-7.5 to -2.3,-188 mL) in the 50 mg once per day and 0.6 (-2.2 to 3.4, 10 mL) and -0.4 (-3.2 to 2.3, -34 mL) in the 100 mg two times per day group. DISCUSSION: Side effects commonly associated with oral pirfenidone in other clinical trials were less frequent with AP01. Mean FVC % predicted remained stable in the 100 mg two times per day group. Further study of AP01 is warranted. TRIAL REGISTRATION NUMBER: ACTRN12618001838202 Australian New Zealand Clinical Trials Registry.
650    _2
$a lidé $7 D006801
650    12
$a antiflogistika nesteroidní $x škodlivé účinky $7 D000894
650    12
$a idiopatická plicní fibróza $x diagnóza $x farmakoterapie $7 D054990
650    12
$a pyridony $x škodlivé účinky $7 D011728
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vitální kapacita $7 D014797
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
651    _2
$a Austrálie $7 D001315
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chaudhuri, Nazia $u University of Ulster, Magee Campus, Londonderry, UK
700    1_
$a Barczyk, Adam $u Department of Pneumonology, Medical University of Silesia, Katowice, Slaskie, Poland
700    1_
$a Wilsher, Margaret L $u Respiratory Services, Auckland District Health Board, Auckland, New Zealand
700    1_
$a Hopkins, Peter $u The Prince Charles Hospital, Brisbane, Queensland, Australia
700    1_
$a Glaspole, Ian $u Department of Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia
700    1_
$a Corte, Tamera Jo $u Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia $u Department of Respiratory Medicine, Royal Brompton Hospital, London, UK
700    1_
$a Šterclová, Martina $u Department of Respiratory Medicine, Thomayer Hospital, Praha, Praha, Czech Republic
700    1_
$a Veale, Antony $u Department of Respiratory Medicine, Queen Elizabeth Hospital, Woodville South, South Australia, Australia
700    1_
$a Jassem, Ewa $u Gdanski Uniwersytet Medyczny, Gdansk, Poland
700    1_
$a Wijsenbeek, Marlies S $u Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
700    1_
$a Grainge, Christopher $u Hunter Medical Research Institute, University of Newcastle, New Castle, New South Wales, Australia
700    1_
$a Piotrowski, Wojciech $u Department of Pneumonology and Allergy, Medical University of Lodz, Lodz, Lodzkie, Poland
700    1_
$a Raghu, Ganesh $u CENTER for Interstitial Lung Diseases, University of Washington, Seattle, Washington, USA $u Department of Medicine, University of Washington, Seattle, Washington, USA $u Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA
700    1_
$a Shaffer, Michele L $u Avalyn Pharma Inc, Seattle, Washington, USA
700    1_
$a Nair, Deepthi $u Avalyn Pharma Inc, Seattle, Washington, USA
700    1_
$a Freeman, Lisa $u Avalyn Pharma Inc, Seattle, Washington, USA
700    1_
$a Otto, Kelly $u Avalyn Pharma Inc, Seattle, Washington, USA
700    1_
$a Montgomery, A Bruce $u Avalyn Pharma Inc, Seattle, Washington, USA bruce.montgomerymd@gmail.com
773    0_
$w MED00004515 $t Thorax $x 1468-3296 $g Roč. 78, č. 9 (2023), s. 882-889
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36948586 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105804 $b ABA008
999    __
$a ok $b bmc $g 2000150 $s 1202817
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 78 $c 9 $d 882-889 $e 20230322 $i 1468-3296 $m Thorax $n Thorax $x MED00004515
LZP    __
$a Pubmed-20231013
Back

Find record

Citation metrics

Archiving options